Matrix metalloproteinase 2 as a potential mediator of vascular smooth muscle cell migration and chronic vascular remodeling in hypertension

Journal of Vascular Research

Volumn 52, Issue 4, 2016, Pages 221-231

  Belo, V A ^a   Guimarães, Danielle A ^a   Castro, Michele Mazzaron ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Extracellular matrix; Hypertension; Matrix metalloproteinase 2; Migration; Vascular remodeling; Vascular smooth muscle cells

Indexed keywords

ANGIOTENSIN II; CADHERIN; COLLAGEN TYPE 4; ELASTIN; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; LAMININ; MATRIX METALLOPROTEINASE 14; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA;

ARTERIAL STIFFNESS; BASEMENT MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHRONIC DISEASE; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME REGULATION; EXTRACELLULAR MATRIX; HUMAN; HYPERTENSION; MECHANICAL STRESS; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; BLOOD PRESSURE; CELL MOTION; CELL SHAPE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOOD PRESSURE; CELL MOVEMENT; CELL SHAPE; CHRONIC DISEASE; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYPERTENSION; MATRIX METALLOPROTEINASE 2; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHENOTYPE; SIGNAL TRANSDUCTION; VASCULAR REMODELING;

EID: 84953775391     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000441621     Document Type: Review

References (107)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365: 217-223
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252
3. Raftopoulos L, Katsi V, Makris T, Tousoulis D, Stefanadis C, Kallikazaros I: Epigenetics, the missing link in hypertension. Life Sci 2015; 129: 22-26
4. Lemarie CA, Tharaux PL, Lehoux S: Extracellular matrix alterations in hypertensive vascular remodeling. J Mol Cell Cardiol 2009; 48: 433-439
5. Castro MM, Tanus-Santos JE. Inhibition of matrix metalloproteinases (MMPs) as a potential strategy to ameliorate hypertensioninduced cardiovascular alterations. Curr Drug Targets 2013; 14: 335-343
6. Hayashi K, Naiki T: Adaptation and remodeling of vascular wall; biomechanical response to hypertension. J Mech Behav Biomed Mater 2009; 2: 3-19
7. Briones AM, Arribas SM, Salaices M: Role of extracellular matrix in vascular remodeling of hypertension. Curr Opin Nephrol Hypertens 2010; 19: 187-194
8. Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L: Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm 2013; 2013: 928315
9. Hua Y, Nair S: Proteases in cardiometabolic diseases: pathophysiology, molecular mechanisms and clinical applications. Biochim Biophys Acta 2015; 1852: 195-208
10. Martinez-Lemus LA, Galinanes EL. Matrix metalloproteinases and small artery remodeling. Drug Discov Today Dis Models 2011; 8: 21-28
11. Mulvany MJ. Small artery remodelling in hypertension. Basic Clin Pharmacol Toxicol 2012; 110: 49-55
12. Briet M, Schiffrin EL. Treatment of arterial remodeling in essential hypertension. Curr Hypertens Rep 2013; 15: 3-9
13. Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001; 19: 921-930
14. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-839
15. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, Gerlach RF, Tanus-Santos JE. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008; 198: 320-331
16. Castro MM, Rizzi E, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 2009; 29: 194-201
17. Castro MM, Rizzi E, Rodrigues GJ, Ceron CS, Bendhack LM, Gerlach RF, Tanus-Santos JE. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med 2009; 46: 1298-1307
18. Castro MM, Tanus-Santos JE, Gerlach RF. Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res 2011; 64: 567-572
19. Ceron CS, Rizzi E, Guimaraes DA, Martins- Oliveira A, Cau SB, Ramos J, Gerlach RF, Tanus-Santos JE. Time course involvement of matrix metalloproteinases in the vascular alterations of renovascular hypertension. Matrix Biol 2012; 31: 261-270
20. Guimaraes DA, Rizzi E, Ceron CS, Oliveira AM, Oliveira DM, Castro MM, Tirapelli CR, Gerlach RF, Tanus-Santos JE. Doxycycline dose-dependently inhibits MMP-2-mediated vascular changes in 2K1C hypertension. Basic Clin Pharmacol Toxicol 2011; 108: 318-325
21. Rizzi E, Castro MM, Prado CM, Silva CA, Fazan R Jr, Rossi MA, Tanus-Santos JE, Gerlach RF. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail 2010; 16: 599-608
22. Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K, Ashby MJ, Cockcroft JR, Wilkinson IB. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25: 372-378
23. Fontana V, Silva PS, Gerlach RF, Tanus-Santos JE. Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin Chim Acta 2012; 413: 656-662
24. Belo VA, Lacchini R, Miranda JA, Lanna CM, Souza-Costa DC, Tanus-Santos JE. Increased activity of MMP-2 in hypertensive obese children is associated with hypoadiponectinemia. Obesity (Silver Spring) 2015; 23: 177-182
25. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R: Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002; 106: 1543-1549
26. Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG, Szczesna-Cordary D, Schulz R: Degradation of myosin light chain in isolated rat hearts subjected to ischemiareperfusion injury: A new intracellular target for matrix metalloproteinase-2. Circulation 2005; 112: 544-552
27. Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R: Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation 2010; 122: 2039-2047
28. Nagase H, Visse R, Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-573
29. Overall CM. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol 2002; 22: 51-86
30. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-21494
31. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007; 211: 19-26
32. Chesler NC, Ku DN, Galis ZS. Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo. Am J Physiol 1999; 277: H2002-H2009
33. Anwar MA, Shalhoub J, Lim CS, Gohel MS, Davies AH. The effect of pressure-induced mechanical stretch on vascular wall differential gene expression. J Vasc Res 2012; 49: 463-478
34. Seo KW, Lee SJ, Kim YH, Bae JU, Park SY, Bae SS, Kim CD. Mechanical stretch increases MMP-2 production in vascular smooth muscle cells via activation of PDGFR-β/Akt signaling pathway. PLoS One 2013; 8: e70437
35. Milkiewicz M, Mohammadzadeh F, Ispanovic E, Gee E, Haas TL. Static strain stimulates expression of matrix metalloproteinase-and VEGF in microvascular endothelium via JNK- And ERK-dependent pathways. J Cell Biochem 2007; 100: 750-761
36. Castier Y, Ramkhelawon B, Riou S, Tedgui A, Lehoux S: Role of NF-kappaB in flow-induced vascular remodeling. Antioxid Redox Signal 2009; 11: 1641-1649
37. Kopaliani I, Martin M, Zatschler B, Bortlik K, Muller B, Deussen A: Cell-specific and endothelium- dependent regulations of matrix metalloproteinase-2 in rat aorta. Basic Res Cardiol 2014; 109: 419
38. Ham SA, Lee H, Hwang JS, Kang ES, Yoo T, Paek KS, Do JT, Park C, Oh JW, Kim JH, Han CW, Seo HG. Activation of peroxisome proliferator- Activated receptor delta inhibits angiotensin II-induced activation of matrix metalloproteinase-2 in vascular smooth muscle cells. J Vasc Res 2014; 51: 221-230
39. Jimenez E, Perez de la Blanca E, Urso L, Gonzalez I, Salas J, Montiel M: Angiotensin II induces MMP 2 activity via FAK/JNK pathway in human endothelial cells. Biochem Biophys Res Commun 2009; 380: 769-774
40. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008; 40: 1362-1378
41. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000; 46: 214-224
42. Lemarie CA, Tharaux PL, Lehoux S: Extracellular matrix alterations in hypertensive vascular remodeling. J Mol Cell Cardiol 2010; 48: 433-439
43. Cau SB, Guimaraes DA, Rizzi E, Ceron CS, Souza LL, Tirapelli CR, Gerlach RF, Tanus- Santos JE. Pyrrolidine dithiocarbamate down-regulates vascular matrix metalloproteinases and ameliorates vascular dysfunction and remodelling in renovascular hypertension. Br J Pharmacol 2011; 164: 372-381
44. Harrison DG, Gongora MC, Guzik TJ, Widder J: Oxidative stress and hypertension. J Am Soc Hypertens 2007; 1: 30-44
45. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923
46. Grote K, Flach I, Luchtefeld M, Akin E, Holland SM, Drexler H, Schieffer B: Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res 2003; 92: e82-e86
47. Rizzi E, Castro MM, Ceron CS, Neto-Neves EM, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF. Tempol inhibits TGF-β and MMPs upregulation and prevents cardiac hypertensive changes. Int J Cardiol 2013; 165: 165-173
48. Chen DD, Dong YG, Liu D, He JG. Epigallocatechin-3-gallate attenuates cardiac hypertrophy in hypertensive rats in part by modulation of mitogen-activated protein kinase signals. Clin Exp Pharmacol Physiol 2009; 36: 925-932
49. Alfonso-Jaume MA, Bergman MR, Mahimkar R, Cheng S, Jin ZQ, Karliner JS, Lovett DH. Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am J Physiol Heart Circ Physiol 2006; 291: H1838-H1846
50. Viappiani S, Nicolescu AC, Holt A, Sawicki G, Crawford BD, Leon H, van Mulligen T, Schulz R: Activation and modulation of 72 kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol 2009; 77: 826-834
51. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H: Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 2001; 276: 29596-29602
52. Schulz R: Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007; 47: 211-242
53. Flamant M, Placier S, Dubroca C, Esposito B, Lopes I, Chatziantoniou C, Tedgui A, Dussaule JC, Lehoux S: Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 2007; 50: 212-218
54. Watts SW, Rondelli C, Thakali K, Li X, Uhal B, Pervaiz MH, Watson RE, Fink GD. Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 2007; 292: H2438-H2448
55. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T: Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998; 12: 12-26
56. Lee HM, Ciancio SG, Tuter G, Ryan ME, Komaroff E, Golub LM. Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug. J Periodontol 2004; 75: 453-463
57. Bouvet C, Gilbert LA, Girardot D, deBlois D, Moreau P: Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 2005; 45: 432-437
58. Martinez-Lemus LA, Zhao G, Galinanes EL, Boone M: Inward remodeling of resistance arteries requires reactive oxygen species-dependent activation of matrix metalloproteinases. Am J Physiol Heart Circ Physiol 2011; 300: H2005-H2015
59. Bouvet C, Moreau S, Blanchette J, de Blois D, Moreau P: Sequential activation of matrix metalloproteinase 9 and transforming growth factor beta in arterial elastocalcinosis. Arterioscler Thromb Vasc Biol 2008; 28: 856-862
60. Uzui H, Lee JD, Shimizu H, Tsutani H, Ueda T: The role of protein-tyrosine phosphorylation and gelatinase production in the migration and proliferation of smooth muscle cells. Atherosclerosis 2000; 149: 51-59
61. Johnson C, Galis ZS. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 2004; 24: 54-60
62. Turner NA, Hall KT, Ball SG, Porter KE. Selective gene silencing of either MMP-2 or MMP-9 inhibits invasion of human saphenous vein smooth muscle cells. Atherosclerosis 2007; 193: 36-43
63. Wang Z, Kong L, Kang J, Vaughn DM, Bush GD, Walding AL, Grigorian AA, Robinson JS Jr, Nakayama DK. Interleukin-lβ induces migration of rat arterial smooth muscle cells through a mechanism involving increased matrix metalloproteinase-2 activity. J Surg Res 2011; 169: 328-336
64. Page-McCaw A, Ewald AJ, Werb Z: Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007; 8: 221-233
65. Aguilera CM, George SJ, Johnson JL, Newby AC. Relationship between type IV collagen degradation, metalloproteinase activity and smooth muscle cell migration and proliferation in cultured human saphenous vein. Cardiovasc Res 2003; 58: 679-688
66. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 2006; 69: 614-624
67. Rizzoni D, Paiardi S, Rodella L, Porteri E, De Ciuceis C, Rezzani R, Boari GE, Zani F, Miclini M, Tiberio GA, Giulini SM, Rosei CA, Bianchi R, Rosei EA. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 2638-2642
68. Gomez-Garre D, Martin-Ventura JL, Granados R, Sancho T, Torres R, Ruano M, Garcia- Puig J, Egido J: Losartan improves resistance artery lesions and prevents CTGF and TGFbeta production in mild hypertensive patients. Kidney Int 2006; 69: 1237-1244
69. Briones AM, Xavier FE, Arribas SM, Gonzalez MC, Rossoni LV, Alonso MJ, Salaices M: Alterations in structure and mechanics of resistance arteries from ouabain-induced hypertensive rats. Am J Physiol Heart Circ Physiol 2006; 291: 10
70. Briones AM, Rodriguez-Criado N, Hernanz R, Garcia-Redondo AB, Rodrigues-Diez RR, Alonso MJ, Egido J, Ruiz-Ortega M, Salaices M: Atorvastatin prevents angiotensin IIinduced vascular remodeling and oxidative stress. Hypertension 2009; 54: 142-149
71. Stringa E, Knauper V, Murphy G, Gavrilovic J: Collagen degradation and platelet-derived growth factor stimulate the migration of vascular smooth muscle cells. J Cell Sci 2000; 113: 2055-2064
72. Taylor JM, Mack CP, Nolan K, Regan CP, Owens GK, Parsons JT. Selective expression of an endogenous inhibitor of FAK regulates proliferation and migration of vascular smooth muscle cells. Mol Cell Biol 2001; 21: 1565-1572
73. Blaschke F, Stawowy P, Kappert K, Goetze S, Kintscher U, Wollert-Wulf B, Fleck E, Graf K: Angiotensin II-augmented migration of VSMCs towards PDGF-BB involves Pyk2 and ERK 1/2 activation. Basic Res Cardiol 2002; 97: 334-342
74. Zargham R, Thibault G: Alpha8beta1 integrin expression in the rat carotid artery: involvement in smooth muscle cell migration and neointima formation. Cardiovasc Res 2005; 65: 813-822
75. Zargham R, Touyz RM, Thibault G: Alpha 8 integrin overexpression in de-differentiated vascular smooth muscle cells attenuates migratory activity and restores the characteristics of the differentiated phenotype. Atherosclerosis 2007; 195: 303-312
76. Wang M, Zhang J, Telljohann R, Jiang L, Wu J, Monticone RE, Kapoor K, Talan M, Lakatta EG. Chronic matrix metalloproteinase inhibition retards age-associated arterial proinflammation and increase in blood pressure. Hypertension 2012; 60: 459-466
77. Arribas SM, Hinek A, Gonzalez MC. Elastic fibres and vascular structure in hypertension. Pharmacol Ther 2006; 111: 771-791
78. Keeley FW, Alatawi A: Response of aortic elastin synthesis and accumulation to developing hypertension and the inhibitory effect of colchicine on this response. Lab Invest 1991; 64: 499-507
79. Arribas SM, Briones AM, Bellingham C, Gonzalez MC, Salaices M, Liu K, Wang Y, Hinek A: Heightened aberrant deposition of hardwearing elastin in conduit arteries of prehypertensive SHR is associated with increased stiffness and inward remodeling. Am J Physiol Heart Circ Physiol 2008; 295: 299-307
80. Mochizuki S, Brassart B, Hinek A: Signaling pathways transduced through the elastin receptor facilitate proliferation of arterial smooth muscle cells. J Biol Chem 2002; 277: 44854-44863
81. Zanetti M, Braghetta P, Sabatelli P, Mura I, Doliana R, Colombatti A, Volpin D, Bonaldo P, Bressan GM. Emilin-1 deficiency induces elastogenesis and vascular cell defects. Mol Cell Biol 2004; 24: 638-650
82. Litteri G, Carnevale D, D Urso A, Cifelli G, Braghetta P, Damato A, Bizzotto D, Landolfi A, Ros FD, Sabatelli P, Facchinello N, Maffei A, Volpin D, Colombatti A, Bressan GM, Lembo G: Vascular smooth muscle emilin-1 is a regulator of arteriolar myogenic response and blood pressure. Arterioscler Thromb Vasc Biol 2012; 32: 2178-2184
83. Wang M, Zhao D, Spinetti G, Zhang J, Jiang LQ, Pintus G, Monticone R, Lakatta EG. Matrix metalloproteinase 2 activation of transforming growth factor-beta1 (TGF-beta1) and TGF-beta1-type II receptor signaling within the aged arterial wall. Arterioscler Thromb Vasc Biol 2006; 26: 1503-1509
84. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFβ activation. J Cell Sci 2003; 116: 217-224
85. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez- Lopez E, Carvajal G, Egido J: TGF-β signaling in vascular fibrosis. Cardiovasc Res 2007; 74: 196-206
86. Ceron CS, Rizzi E, Guimaraes DA, Martins- Oliveira A, Gerlach RF, Tanus-Santos JE. Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF-β and MMPs, and decreases vascular remodeling in renovascular hypertension. Free Radic Biol Med 2013; 65: 47-56
87. O Callaghan CJ, Williams B: Mechanical strain-induced extracellular matrix production by human vascular smooth muscle cells: role of TGF-β1. Hypertension 2000; 36: 319-324
88. Zacchigna L, Vecchione C, Notte A, Cordenonsi M, Dupont S, Maretto S, Cifelli G, Ferrari A, Maffei A, Fabbro C, Braghetta P, Marino G, Selvetella G, Aretini A, Colonnese C, Bettarini U, Russo G, Soligo S, Adorno M, Bonaldo P, Volpin D, Piccolo S, Lembo G, Bressan GM. Emilin1 links TGF-β maturation to blood pressure homeostasis. Cell 2006; 124: 929-942
89. Sun Z, Parrish AR, Hill MA, Meininger GA. N-cadherin, a vascular smooth muscle cellcell adhesion molecule: function and signaling for vasomotor control. Microcirculation 2014; 21: 208-218
90. Yonemura S: Cadherin-actin interactions at adherens junctions. Curr Opin Cell Biol 2011; 23: 515-522
91. Blindt R, Bosserhoff AK, Dammers J, Krott N, Demircan L, Hoffmann R, Hanrath P, Weber C, Vogt F: Downregulation of N-cadherin in the neointima stimulates migration of smooth muscle cells by RhoA deactivation. Cardiovasc Res 2004; 62: 212-222
92. Uglow EB, Slater S, Sala-Newby GB, Aguilera- Garcia CM, Angelini GD, Newby AC, George SJ. Dismantling of cadherin-mediated cellcell contacts modulates smooth muscle cell proliferation. Circ Res 2003; 92: 1314-1321
93. Dwivedi A, Slater SC, George SJ. MMP-9 and -12 cause N-cadherin shedding and thereby β-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc Res 2009; 81: 178-186
94. Resink TJ, Philippova M, Joshi MB, Kyriakakis E, Erne P: Cadherins and cardiovascular disease. Swiss Med Wkly 2009; 139: 122-134
95. Covington MD, Burghardt RC, Parrish AR. Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14). Am J Physiol Renal Physiol 2006; 290: 2
96. Jang YN, Jung YS, Lee SH, Moon CH, Kim CH, Baik EJ. Calpain-mediated N-cadherin proteolytic processing in brain injury. J Neurosci 2009; 29: 5974-5984
97. Iwazu Y, Muto S, Hirahara I, Fujisawa G, Takeda S, Kusano E: Matrix metalloproteinase 2 induces epithelial-mesenchymal transition in proximal tubules from the luminal side and progresses fibrosis in mineralocorticoid/salt-induced hypertensive rats. J Hypertens 2011; 29: 2440-2453
98. Jackson TY, Sun Z, Martinez-Lemus LA, Hill MA, Meininger GA. N-cadherin and integrin blockade inhibit arteriolar myogenic reactivity but not pressure-induced increases in intracellular Ca. Front Physiol 2010; 1: 165
99. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516
100. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004; 84: 767-801
101. Pfisterer L, Feldner A, Hecker M, Korff T: Hypertension impairs myocardin function: A novel mechanism facilitating arterial remodelling. Cardiovasc Res 2012; 96: 120-129
102. Hu JJ, Ambrus A, Fossum TW, Miller MW, Humphrey JD, Wilson E: Time courses of growth and remodeling of porcine aortic media during hypertension: A quantitative immunohistochemical examination. J Histochem Cytochem 2008; 56: 359-370
103. Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG., et al. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 1994; 75: 41-54
104. Johnson JL, van Eys GJ, Angelini GD, George SJ. Injury induces dedifferentiation of smooth muscle cells and increased matrix- degrading metalloproteinase activity in human saphenous vein. Arterioscler Thromb Vasc Biol 2001; 21: 1146-1151
105. Jiang L, Wang M, Zhang J, Monticone RE, Telljohann R, Spinetti G, Pintus G, Lakatta EG. Increased aortic calpain-1 activity mediates age-associated angiotensin II signaling of vascular smooth muscle cells. PLoS One 2008; 3: e2231
106. Weisbrod RM, Shiang T, Al Sayah L, Fry JL, Bajpai S, Reinhart-King CA, Lob HE, Santhanam L, Mitchell G, Cohen RA, Seta F: Arterial stiffening precedes systolic hypertension in diet-induced obesity. Hypertension 2013; 62: 1105-1110
107. Castro MM, Rizzi E, Ceron CS, Guimaraes DA, Rodrigues GJ, Bendhack LM, Gerlach RF, Tanus-Santos JE. Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability. Nitric Oxide 2012; 26: 162-168